 | • レポートコード：MRC23Q36139 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（2-3日） • 産業分類：医療 |
| Single User | ￥429,200 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥858,400 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のリポソーム開発サービス市場について調査・分析し、世界のリポソーム開発サービス市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（リポソーム、脂質ナノ粒子）、用途別セグメント分析（前臨床、臨床、商用）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Precision NanoSystems、Evonik、Merck KGaA、Genevant Sciences、Exelead、Avanti Polar Lipids、Nippon Fine Chemical、Lipoid、Polymun Scientific、Corden Pharma、Acuitas Therapeutics、Creative Biolabs、Creative Biostructure、T&T Scientific、FormuMax Scientific、PlantaCorp、CD Bioparticlesなどが含まれています。世界のリポソーム開発サービス市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、リポソーム開発サービス市場規模を推定する際に考慮しました。本レポートは、リポソーム開発サービスの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、リポソーム開発サービスに関するビジネス上の意思決定に役立てることを目的としています。 ・リポソーム開発サービス市場の概要 - リポソーム開発サービスのタイプ別セグメント - 世界のリポソーム開発サービス市場規模：タイプ別分析（リポソーム、脂質ナノ粒子） - リポソーム開発サービスの用途別セグメント - 世界のリポソーム開発サービス市場規模：用途別分析（前臨床、臨床、商用） - 世界のリポソーム開発サービス市場規模予測（2018年-2029年） ・リポソーム開発サービス市場の成長トレンド - リポソーム開発サービスの地域別市場規模（2018年-2029年） - リポソーム開発サービス市場ダイナミクス - リポソーム開発サービスの業界動向 - リポソーム開発サービス市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：リポソーム、脂質ナノ粒子 - 世界のリポソーム開発サービスのタイプ別市場規模（2018年-2023年） - 世界のリポソーム開発サービスのタイプ別市場規模（2024年-2029年） ・用途別セグメント：前臨床、臨床、商用 - 世界のリポソーム開発サービスの用途別市場規模（2018年-2023年） - 世界のリポソーム開発サービスの用途別市場規模（2024年-2029年） ・リポソーム開発サービスの地域別市場規模 - 北米のリポソーム開発サービス市場規模（2018年-2029年） - アメリカのリポソーム開発サービス市場規模（2018年-2029年） - ヨーロッパのリポソーム開発サービス市場規模（2018年-2029年） - アジア太平洋のリポソーム開発サービス市場規模（2018年-2029年） - 中国のリポソーム開発サービス市場規模（2018年-2029年） - 日本のリポソーム開発サービス市場規模（2018年-2029年） - 韓国のリポソーム開発サービス市場規模（2018年-2029年） - インドのリポソーム開発サービス市場規模（2018年-2029年） - オーストラリアのリポソーム開発サービス市場規模（2018年-2029年） - 中南米のリポソーム開発サービス市場規模（2018年-2029年） - 中東・アフリカのリポソーム開発サービス市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Precision NanoSystems、Evonik、Merck KGaA、Genevant Sciences、Exelead、Avanti Polar Lipids、Nippon Fine Chemical、Lipoid、Polymun Scientific、Corden Pharma、Acuitas Therapeutics、Creative Biolabs、Creative Biostructure、T&T Scientific、FormuMax Scientific、PlantaCorp、CD Bioparticles ・アナリストの観点/結論 ・調査方法とデータソース |
Liposomes are a type of nano-sized phospholipid bubbles, which have attracted much attention as potential drug carriers. Liposomes are highly biocompatible and easy to control in vivo and can be loaded with a broad variety of drugs, DNA, and diagnostic agents. To date, a variety of liposomal drugs are under development and some of them are already approved for clinical use.
Highlights
The global Liposome Development Service market was valued at US$ 1135 million in 2022 and is anticipated to reach US$ 1807.1 million by 2029, witnessing a CAGR of 8.1% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global key players of liposome development service include Precision NanoSystems, Evonik, Merck KGaA, Genevant Sciences, Exelead, etc. The top two players hold a share over 52%. North America is the largest market, has a share about 61%, followed by Europe and Asia-Pacific, with share 26% and 11%, separately. In terms of product type, Lipid Nanoparticles is the largest segment, occupied for a share of 62%, and in terms of application, Commercial has a share about 86 percent.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Liposome Development Service, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liposome Development Service.
The Liposome Development Service market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Liposome Development Service market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Liposome Development Service companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Precision NanoSystems
Evonik
Merck KGaA
Genevant Sciences
Exelead
Avanti Polar Lipids
Nippon Fine Chemical
Lipoid
Polymun Scientific
Corden Pharma
Acuitas Therapeutics
Creative Biolabs
Creative Biostructure
T&T Scientific
FormuMax Scientific
PlantaCorp
CD Bioparticles
Segment by Type
Liposomes
Lipid Nanoparticles
Segment by Application
Preclinical
Clinical
Commercial
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Liposome Development Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Liposome Development Service Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Liposomes
1.2.3 Lipid Nanoparticles
1.3 Market by Application
1.3.1 Global Liposome Development Service Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Preclinical
1.3.3 Clinical
1.3.4 Commercial
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Liposome Development Service Market Perspective (2018-2029)
2.2 Liposome Development Service Growth Trends by Region
2.2.1 Global Liposome Development Service Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Liposome Development Service Historic Market Size by Region (2018-2023)
2.2.3 Liposome Development Service Forecasted Market Size by Region (2024-2029)
2.3 Liposome Development Service Market Dynamics
2.3.1 Liposome Development Service Industry Trends
2.3.2 Liposome Development Service Market Drivers
2.3.3 Liposome Development Service Market Challenges
2.3.4 Liposome Development Service Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Liposome Development Service Players by Revenue
3.1.1 Global Top Liposome Development Service Players by Revenue (2018-2023)
3.1.2 Global Liposome Development Service Revenue Market Share by Players (2018-2023)
3.2 Global Liposome Development Service Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Liposome Development Service Revenue
3.4 Global Liposome Development Service Market Concentration Ratio
3.4.1 Global Liposome Development Service Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Liposome Development Service Revenue in 2022
3.5 Liposome Development Service Key Players Head office and Area Served
3.6 Key Players Liposome Development Service Product Solution and Service
3.7 Date of Enter into Liposome Development Service Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Liposome Development Service Breakdown Data by Type
4.1 Global Liposome Development Service Historic Market Size by Type (2018-2023)
4.2 Global Liposome Development Service Forecasted Market Size by Type (2024-2029)
5 Liposome Development Service Breakdown Data by Application
5.1 Global Liposome Development Service Historic Market Size by Application (2018-2023)
5.2 Global Liposome Development Service Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Liposome Development Service Market Size (2018-2029)
6.2 North America Liposome Development Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Liposome Development Service Market Size by Country (2018-2023)
6.4 North America Liposome Development Service Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Liposome Development Service Market Size (2018-2029)
7.2 Europe Liposome Development Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Liposome Development Service Market Size by Country (2018-2023)
7.4 Europe Liposome Development Service Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Liposome Development Service Market Size (2018-2029)
8.2 Asia-Pacific Liposome Development Service Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Liposome Development Service Market Size by Region (2018-2023)
8.4 Asia-Pacific Liposome Development Service Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Liposome Development Service Market Size (2018-2029)
9.2 Latin America Liposome Development Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Liposome Development Service Market Size by Country (2018-2023)
9.4 Latin America Liposome Development Service Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Liposome Development Service Market Size (2018-2029)
10.2 Middle East & Africa Liposome Development Service Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Liposome Development Service Market Size by Country (2018-2023)
10.4 Middle East & Africa Liposome Development Service Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Precision NanoSystems
11.1.1 Precision NanoSystems Company Detail
11.1.2 Precision NanoSystems Business Overview
11.1.3 Precision NanoSystems Liposome Development Service Introduction
11.1.4 Precision NanoSystems Revenue in Liposome Development Service Business (2018-2023)
11.1.5 Precision NanoSystems Recent Development
11.2 Evonik
11.2.1 Evonik Company Detail
11.2.2 Evonik Business Overview
11.2.3 Evonik Liposome Development Service Introduction
11.2.4 Evonik Revenue in Liposome Development Service Business (2018-2023)
11.2.5 Evonik Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Detail
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Liposome Development Service Introduction
11.3.4 Merck KGaA Revenue in Liposome Development Service Business (2018-2023)
11.3.5 Merck KGaA Recent Development
11.4 Genevant Sciences
11.4.1 Genevant Sciences Company Detail
11.4.2 Genevant Sciences Business Overview
11.4.3 Genevant Sciences Liposome Development Service Introduction
11.4.4 Genevant Sciences Revenue in Liposome Development Service Business (2018-2023)
11.4.5 Genevant Sciences Recent Development
11.5 Exelead
11.5.1 Exelead Company Detail
11.5.2 Exelead Business Overview
11.5.3 Exelead Liposome Development Service Introduction
11.5.4 Exelead Revenue in Liposome Development Service Business (2018-2023)
11.5.5 Exelead Recent Development
11.6 Avanti Polar Lipids
11.6.1 Avanti Polar Lipids Company Detail
11.6.2 Avanti Polar Lipids Business Overview
11.6.3 Avanti Polar Lipids Liposome Development Service Introduction
11.6.4 Avanti Polar Lipids Revenue in Liposome Development Service Business (2018-2023)
11.6.5 Avanti Polar Lipids Recent Development
11.7 Nippon Fine Chemical
11.7.1 Nippon Fine Chemical Company Detail
11.7.2 Nippon Fine Chemical Business Overview
11.7.3 Nippon Fine Chemical Liposome Development Service Introduction
11.7.4 Nippon Fine Chemical Revenue in Liposome Development Service Business (2018-2023)
11.7.5 Nippon Fine Chemical Recent Development
11.8 Lipoid
11.8.1 Lipoid Company Detail
11.8.2 Lipoid Business Overview
11.8.3 Lipoid Liposome Development Service Introduction
11.8.4 Lipoid Revenue in Liposome Development Service Business (2018-2023)
11.8.5 Lipoid Recent Development
11.9 Polymun Scientific
11.9.1 Polymun Scientific Company Detail
11.9.2 Polymun Scientific Business Overview
11.9.3 Polymun Scientific Liposome Development Service Introduction
11.9.4 Polymun Scientific Revenue in Liposome Development Service Business (2018-2023)
11.9.5 Polymun Scientific Recent Development
11.10 Corden Pharma
11.10.1 Corden Pharma Company Detail
11.10.2 Corden Pharma Business Overview
11.10.3 Corden Pharma Liposome Development Service Introduction
11.10.4 Corden Pharma Revenue in Liposome Development Service Business (2018-2023)
11.10.5 Corden Pharma Recent Development
11.11 Acuitas Therapeutics
11.11.1 Acuitas Therapeutics Company Detail
11.11.2 Acuitas Therapeutics Business Overview
11.11.3 Acuitas Therapeutics Liposome Development Service Introduction
11.11.4 Acuitas Therapeutics Revenue in Liposome Development Service Business (2018-2023)
11.11.5 Acuitas Therapeutics Recent Development
11.12 Creative Biolabs
11.12.1 Creative Biolabs Company Detail
11.12.2 Creative Biolabs Business Overview
11.12.3 Creative Biolabs Liposome Development Service Introduction
11.12.4 Creative Biolabs Revenue in Liposome Development Service Business (2018-2023)
11.12.5 Creative Biolabs Recent Development
11.13 Creative Biostructure
11.13.1 Creative Biostructure Company Detail
11.13.2 Creative Biostructure Business Overview
11.13.3 Creative Biostructure Liposome Development Service Introduction
11.13.4 Creative Biostructure Revenue in Liposome Development Service Business (2018-2023)
11.13.5 Creative Biostructure Recent Development
11.14 T&T Scientific
11.14.1 T&T Scientific Company Detail
11.14.2 T&T Scientific Business Overview
11.14.3 T&T Scientific Liposome Development Service Introduction
11.14.4 T&T Scientific Revenue in Liposome Development Service Business (2018-2023)
11.14.5 T&T Scientific Recent Development
11.15 FormuMax Scientific
11.15.1 FormuMax Scientific Company Detail
11.15.2 FormuMax Scientific Business Overview
11.15.3 FormuMax Scientific Liposome Development Service Introduction
11.15.4 FormuMax Scientific Revenue in Liposome Development Service Business (2018-2023)
11.15.5 FormuMax Scientific Recent Development
11.16 PlantaCorp
11.16.1 PlantaCorp Company Detail
11.16.2 PlantaCorp Business Overview
11.16.3 PlantaCorp Liposome Development Service Introduction
11.16.4 PlantaCorp Revenue in Liposome Development Service Business (2018-2023)
11.16.5 PlantaCorp Recent Development
11.17 CD Bioparticles
11.17.1 CD Bioparticles Company Detail
11.17.2 CD Bioparticles Business Overview
11.17.3 CD Bioparticles Liposome Development Service Introduction
11.17.4 CD Bioparticles Revenue in Liposome Development Service Business (2018-2023)
11.17.5 CD Bioparticles Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details